• Home
  • 2.0 LPBI Executive Summary
  • 1.0 LPBI Executive Summary
  • 2.0 LPBI Brochure
  • Coronavirus, SARS-CoV-2 Portal
  • Knowledge PORTALS System (KPS)
  • Journal PharmaceuticalIntelligence.com
  • 2020-21 VISTA 1.0 LPBI
  • LPBI Group’s History
  • 2020-21 VISION – 2.0 LPBI
  • BioMed e-Series
  • Press Coverage
  • Investor Relations
  • Our TEAM
  • Founder
  • Funding, Deals & Partnerships
  • LPBI Group News
  • CALENDAR
  • Testimonials about LPBI
  • DrugDiscovery @LPBI Group
  • Medical 3D Printing
  • e-VOICES Podcasting
  • LPBI Newsletters
  • Customer Surveys
  • Health Care INVESTOR’s Corner ($)
  • 2020 Summer Internship Portal
  • 2021 Medical Text Analysis (NLP)
  • Artificial Intelligence: Genomics & Cancer
  • Blockchain Transactions Network Ecosystem
  • Contact Us
  • 1.0 LPBI Brochure

Leaders in Pharmaceutical Business Intelligence (LPBI) Group

Funding, Deals & Partnerships: BIOLOGICS & MEDICAL DEVICES; BioMed e-Series; Medicine and Life Sciences Scientific Journal – http://PharmaceuticalIntelligence.com

Feeds:
Posts
Comments

Diabetes – A Combination Drug Therapy to induce Insulin Production by Pancreatic Beta Cells (PPAR-gamma, Leptin, ..)

Part I

Articles by LPBI Group’s Team Member

Adipocyte Derived Stroma Cells: Their Usage in Regenerative Medicine and Reprogramming into Pancreatic Beta-Like Cells

Curator: Evelina Cohn, PhD

Fat Cells Reprogrammed to Make Insulin

Curator: Larry H. Bernstein, MD, FCAP

 

Part II

Diabetes: All Drugs in Development

Curator: Stephen J Williams, PhD

 

 

Table 1. Drugs in Development1–3
Generic/Code Name Manufacturer Indication Phase
DPP-4 Inhibitors
Alogliptin/SYR-322 Takeda Type 2 diabetes NDA submitted
AMG 222/ALS2- 0426 Amgen/Servier Type 2 diabetes 2
Dutogliptin/PHX1149 Phenomix/Forest Laboratories Type 2 diabetes 3
KRP-204/N-5984 Kyorin Type 2 diabetes 2
KRP-104 Kyorin/ActivX Biosciences Type 2 diabetes 2
Linagliptin/BI-1356 Boehringer Ingelheim Type 2 diabetes 3
Melogliptin/GRC 8200 Glenmark Pharmaceuticals Type 2 diabetes 2
MP-513 Mitsubishi Tanabe Pharma Type 2 diabetes 2
PF 734200 Pfizer Type 2 diabetes 2
R1579 Roche/Chugai Type 2 diabetes 2
Saxagliptin/BMS-477118 Bristol-Myers Squibb/AstraZeneca Type 2 diabetes NDA submitted
SYR 472 Takeda Type 2 diabetes 2
TA-6666 Mitsubishi Tanabe Type 2 diabetes 2
Vildagliptin Novartis Type 2 diabetes NDA submitted
GLP-1 Analogs
Albiglutide/GSK716155 GSK Type 2 diabetes 2
AVE0010/ZP-10 Sanofi-Aventis Type 2 diabetes 3
CJC-1134-PC/PC-DAC: Exendin-4 ConjuChem Type 2 diabetes 2
Exenatide LAR Amylin/Alkermes/Lilly Type 2 diabetes 3
Liraglutide/NN2211 Novo Nordisk Type 2 diabetes NDA submitted
LY 2189265 Lilly Type 2 diabetes 3
NN9535 Novo Nordisk Type 2 diabetes 2
Taspoglutide/R1583/BIM-51077 Roche/Ipsen Type 2 diabetes 3
Biguanides
Metformin gum/buccal Generex/Fertin Pharma Type 2 diabetes 2
Thiazolidinediones/PPAR-γ Agonists
Balaglitazone/DRF-2593 Dr. Reddy’s Laboratories/Rheoscience Type 2 diabetes 3
Mitoglitazone/MDSC 0160 Metabolic Solutions Development Type 2 diabetes 2
Netoglitazone/MCC-55 Mitsubishi Tanabe/Perlegen Type 2 diabetes 2
Rivoglitazone/CS-011 Daiichi-Sankyo Type 2 diabetes 3
Other PPAR Agonists
Aleglitazar/R1439 Roche Type 2 diabetes 2
Indeglitazar Pexxikon/Wyeth Type 2 diabetes 2
INT 131/AMG131 Amgen/InteKrin Therapeutics Type 2 diabetes 2
MBX 2044 Metabolex/Ortho-McNeil Type 2 diabetes 2
Metaglidasen/MBX 102/JNJ-39659100 Metabolex/Ortho-McNeil Type 2 diabetes 2
ONO-5129 Ono Type 2 diabetes 2
PLX204/PPM-204 Plexxikon/Wyeth Type 2 diabetes 2
Selective Sodium Glucose Cotransporter Inhibitors
ASP1941 Astellas Type 2 diabetes 2
AVE2268 Sanofi-Aventis Type 2 diabetes 2
BI 10773 Boehringer Ingelheim Type 2 diabetes 2
Dapagliflozin/BMS512148 AstraZeneca/Bristol-Myers Squibb Type 2 diabetes 3
KGT-1681 GSK/Kissei Type 2 diabetes 2
Remogliflozin/189075 GSK/Kissei Type 2 diabetes 2
TA-7284 Mitsubishi Tanabe/Ortho McNeil Type 2 diabetes 2
YM543 Astellas Type 2 diabetes 2
Glinides
Mitiglinide Elixir Pharmaceuticals Type 2 diabetes 3
Insulins
Inhaled Technosphere insulin Mannkind Type 1 and type 2 diabetes 3
Insulin intranasal Bentley Type 1 and type 2 diabetes 2
Insulin intranasal MDRNA Type 2 diabetes 2
Oral HDV insulin Diasome Type 2 diabetes 2
Oral insulin spray Generex Type 1 and type 2 diabetes 3
NN1250 insulin analog for
injection
Novo Nordisk Type 1 and type 2 diabetes 2
NN5401 insulin analog for
injection
Novo Nordisk Type 1 and type 2 diabetes 2
Rapid-acting insulin for injection Biodel Type 1 and type 2 diabetes 3
Recombinant human hyaluroindase (rHuPH20)/insulin co-formulation for injection Halozyme Therapeutics Type 1 diabetes 2
Other Drugs in Development
Generic/Code Name Manufacturer Mechanism Indication
AJD101 Daiichi Sankyo Activates insulin signaling pathway Type 2 diabetes
AKP- 020 Akesis Vanadium compound Type 2 diabetes
AMG-108 Amgen Interleukin-1 inhibitor Type 2 diabetes
AZD6370 AstraZeneca Glucokinase activator Type 2 diabetes
Bromocriptine VeroScience Dopamine D2 receptor
agonist
Type 2 diabetes
Canakinumab/ACZ885 Novartis Anti-interleukin-1 beta antibody Type 2 diabetes
Colestimide Mitsubishi-Tanabe Unknown Type 2 diabetes
Bezafibrate + diflunisal/ CRx-401 CombinatoRx Unknown Type 2 diabetes
DIO-902/2S,4R ketoconazole DiObex Cortisol synthesis inhibitor Type 2 diabetes
DM-71/bethanechol and N-acetyl cysteine Diamedica Unknown Type 2 diabetes
DM-83/combination of two generic compounds Diamedica Unknown Type 2 diabetes
E1 INT Transition Therapeutics Islet regeneration factor Type 1 and type 2 diabetes
Eprodisate/NC-503 Bellus Health Serum amyloid A protein inhibitor ?
Ex vivo cultured adult human mesenchymal stem cells Osiris Mesenchymal stem cell
therapy
Type 1 diabetes
HE3286 Hollis-Eden Insulin sensitizer (NF-kappaB pathway/TLR4 receptor) Type 2 diabetes
INCB 13739 Incyte 11-beta hydroxysteroid dehydrogenase inhibitor Type 2 diabetes
INCB 19602 Incyte GPR109A receptor agonist / HM74a agonist Type 2 diabetes
INGAP peptide Kinexum Islet neogenesis associated protein Type 1 and type 2 diabetes
ISIS 113715 Isis PTP1B Type 2 diabetes
MB 07803 Metabasis/Daiichi
Sankyo
Fructose-1,6-bisphosphatase inhibitor Type 2 diabetes
MK 0893 Merck Unknown Type 2 diabetes
MK 0941 Merck Unknown Type 2 diabetes
Otelixizumab/TRX4 GSK, Tolerx Anti-CD3 MAb Type 1 diabetes
rhGAD65/recombinant human glutamic acid decarboxylase Diamyd Therapeutics Vaccine/induces immunmotolerization Type 1 diabetes
Succinobucol/AGI 1067 AtheroGenics Antioxidant/vascular cell adhesion molecule-1 Type 2 diabetes
Tagatose Spherix Attenuates intestinal glucose absorption Type 2 diabetes
Teplizumab/MGA031/ hOKT3gamma1(Ala-Ala) Lilly/MacroGenics Anti-CD3 MAb Type 1 diabetes
TT-223 Lilly/Transition Therapeutics Gastrin analog Type 1 and type 2 diabetes

 

  • Enter your email address to follow this blog and receive notifications of new posts by email.

    Join 2,054 other followers

  • Recent Posts

    • World Leaders to meet during Davos Agenda in a crucial year to rebuild trust January 18, 2021
    • Joe Biden Announced Science Team Nominations for the New Administration January 17, 2021
    • Potential Interest in LPBI Group’s BioMed e-Series January 17, 2021
    • Dysregulation of ncRNAs in association with Neurodegenerative Disorders January 11, 2021
    • Early Details of Brain Damage in COVID-19 Patients January 9, 2021
    • Cancer treatment using CRISPR-based Genome Editing System January 9, 2021
    • e-Voices Podcasting by LPBI: Celebrating Podcast #3 in an Audio Library on leading Scientists and Key Opinion Leaders in Biological Sciences January 9, 2021
    • Retrospective Study of National Danish Registry Sheds Light on Cardiotoxic Risks of Immune Checkpoint Inhibitors January 8, 2021
    • Leaders in Pharmaceutical Business Intelligence & youngStartup Ventures: Venture Summit Virtual Connect West, March 16th -18th 2021 featuring a dedicated Lifesciences / Healthcare Track   January 6, 2021
    • Global Tert-Amylbenzene Market Size by Application, Regional Outlook, Price Trend, Competitive Market Share & Forecast, 2020 – 2026 January 6, 2021
  • Archives

  • Categories

  • Meta

    • Register
    • Log in
    • Entries feed
    • Comments feed
    • WordPress.com
    • 2012pharmaceutical
    • Amandeep Kaur
    • Aashir Awan, Phd
    • Adina Hazan
    • Alan F. Kaul, PharmD., MS, MBA, FCCP
    • alexcrystal6
    • anamikasarkar
    • apreconasia
    • aviralvatsa
    • David Orchard-Webb, PhD
    • danutdaagmailcom
    • Demet Sag, Ph.D., CRA, GCP
    • Daniel Menzin
    • Dror Nir
    • dsmolyar
    • evelinacohn
    • Gail S Thornton
    • Irina Robu
    • jayzmit48
    • jdpmd
    • jshertok
    • kellyperlman
    • Ed Kislauskis
    • larryhbern
    • Madison Davis
    • marzankhan
    • megbaker58
    • ofermar2020
    • pkandala
    • Rosalind Codrington, PhD
    • ritusaxena
    • Rick Mandahl
    • sjwilliamspa
    • stuartlpbi
    • Dr. Sudipta Saha
    • tildabarliya
    • zraviv06
    • zs22

Blog at WordPress.com.

WPThemes.